<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">32526057</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-1331</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>10</Issue><PubDate><Year>2020</Year><Month>Oct</Month></PubDate></JournalIssue><Title>European journal of neurology</Title><ISOAbbreviation>Eur J Neurol</ISOAbbreviation></Journal><ArticleTitle>Amyotrophic lateral sclerosis: a clinical review.</ArticleTitle><Pagination><StartPage>1918</StartPage><EndPage>1929</EndPage><MedlinePgn>1918-1929</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ene.14393</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder affecting primarily the motor system, but in which extra-motor manifestations are increasingly recognized. The loss of upper and lower motor neurons in the motor cortex, the brain stem nuclei and the anterior horn of the spinal cord gives rise to progressive muscle weakness and wasting. ALS often has a focal onset but subsequently spreads to different body regions, where failure of respiratory muscles typically limits survival to 2-5&#xa0;years after disease onset. In up to 50% of cases, there are extra-motor manifestations such as changes in behaviour, executive dysfunction and language problems. In 10%-15% of patients, these problems are severe enough to meet the clinical criteria of frontotemporal dementia (FTD). In 10% of ALS patients, the family history suggests an autosomal dominant inheritance pattern. The remaining 90% have no affected family members and are classified as sporadic ALS. The causes of ALS appear to be heterogeneous and are only partially understood. To date, more than 20 genes have been associated with ALS. The most common genetic cause is a hexanucleotide repeat expansion in the C9orf72 gene, responsible for 30%-50% of familial ALS and 7% of sporadic ALS. These expansions are also a frequent cause of frontotemporal dementia, emphasizing the molecular overlap between ALS and FTD. To this day there is no cure or effective treatment for ALS and the cornerstone of treatment remains multidisciplinary care, including nutritional and respiratory support and symptom management. In this review, different aspects of ALS are discussed, including epidemiology, aetiology, pathogenesis, clinical features, differential diagnosis, investigations, treatment and future prospects.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. European Journal of Neurology published by John Wiley &amp; Sons Ltd on behalf of European Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Masrori</LastName><ForeName>P</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-8247-1866</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, Experimental Neurology, KU Leuven - University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Neurobiology, Center for Brain and Disease Research, VIB, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Damme</LastName><ForeName>P</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-4010-2357</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, Experimental Neurology, KU Leuven - University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Neurobiology, Center for Brain and Disease Research, VIB, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>C1-C14-17-107</GrantID><Agency>KU Leuven</Agency><Country>International</Country></Grant><Grant><Agency>Opening the Future Fund (KU Leuven)</Agency><Country>International</Country></Grant><Grant><Agency>the Fund for Scientific Research Flanders (FWO-Flanders)</Agency><Country>International</Country></Grant><Grant><Agency>the ALS Liga Belgium</Agency><Country>International</Country></Grant><Grant><Agency>Een Hart voor ALS</Agency><Country>International</Country></Grant><Grant><Agency>'</Agency><Country>International</Country></Grant><Grant><Agency>Laeversfonds voor ALS Onderzoek</Agency><Country>International</Country></Grant><Grant><Agency>Val&#xe9;ry Perrier Race against ALS Fund</Agency><Country>International</Country></Grant><Grant><GrantID>SAO-FRA 2017/023</GrantID><Agency>the Alzheimer Research Foundation</Agency><Country>International</Country></Grant><Grant><GrantID>VIND 135043</GrantID><Agency>the Flemish Government initiated Flanders Impulse Program on Networks for Dementia Research</Agency><Country>International</Country></Grant><Grant><Agency>Flanders Innovation and Enterpreneurship (IWT grants Project MinE and iPSCAF)</Agency><Country>International</Country></Grant><Grant><Agency>the Belgian National Lottery</Agency><Country>International</Country></Grant><Grant><Agency>the Latran Foundation</Agency><Country>International</Country></Grant><Grant><GrantID>755094</GrantID><Agency>the European Union's Horizon 2020 research and innovation programme</Agency><Country>International</Country></Grant><Grant><Agency>the European Union's ERA-Net for Research Programmes on Rare Diseases (INTEGRALS)</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Neurol</MedlineTA><NlmUniqueID>9506311</NlmUniqueID><ISSNLinking>1351-5101</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">TDP-43 pathology</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">sporadic and familial ALS</Keyword></KeywordList><CoiStatement>The authors declare no financial or other conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32526057</ArticleId><ArticleId IdType="pmc">PMC7540334</ArticleId><ArticleId IdType="doi">10.1111/ene.14393</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O, Al&#x2010;Chalabi A, Chio A, et al Amyotrophic lateral sclerosis. Nat Rev Dis Primers 2017; 3: 17085.</Citation><ArticleIdList><ArticleId IdType="pubmed">29052611</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al&#x2010;Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med 2017; 377: 162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Hardiman O, Chio A, et al Amyotrophic lateral sclerosis. Lancet 2017; 390: 2084&#x2013;2098.</Citation><ArticleIdList><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Phukan J, Pender NP, Hardiman O. Cognitive impairment in amyotrophic lateral sclerosis. Lancet Neurol 2007; 6: 994&#x2013;1003.</Citation><ArticleIdList><ArticleId IdType="pubmed">17945153</ArticleId></ArticleIdList></Reference><Reference><Citation>Neary D, Snowden JS, Gustafson L, et al Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998; 51: 1546&#x2013;1554.</Citation><ArticleIdList><ArticleId IdType="pubmed">9855500</ArticleId></ArticleIdList></Reference><Reference><Citation>Burrell JR, Kiernan MC, Vucic S, Hodges JR. Motor neuron dysfunction in frontotemporal dementia. Brain 2011; 134: 2582&#x2013;2594.</Citation><ArticleIdList><ArticleId IdType="pubmed">21840887</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, et al Ubiquitinated TDP&#x2010;43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006; 314: 130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Dengler R, Eisen A, et al Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol 2008; 119: 497&#x2013;503.</Citation><ArticleIdList><ArticleId IdType="pubmed">18164242</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrooten M, Smetcoren C, Robberecht W, Van Damme P. Benefit of the Awaji diagnostic algorithm for amyotrophic lateral sclerosis: a prospective study. Ann Neurol 2011; 70: 79&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">21437935</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Al&#x2010;Chalabi A, Baker MR, et al A proposal for new diagnostic criteria for ALS. Clin Neurophysiol 2020; 131: 1975&#x2013;1978.</Citation><ArticleIdList><ArticleId IdType="pubmed">32387049</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994; 330: 585&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol 2014; 13: 1127&#x2013;1138.</Citation><ArticleIdList><ArticleId IdType="pubmed">25316019</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G, Traynor BJ, Hardiman O, et al Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry 2010; 81: 385&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850819</ArticleId><ArticleId IdType="pubmed">19710046</ArticleId></ArticleIdList></Reference><Reference><Citation>Collaborators GBDMND . Global, regional, and national burden of motor neuron diseases 1990&#x2013;2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018; 17: 1083&#x2013;1097.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6234315</ArticleId><ArticleId IdType="pubmed">30409709</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin B, Boumediene F, Logroscino G, et al Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta&#x2010;analysis. Int J Epidemiol 2017; 46: 57&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5407171</ArticleId><ArticleId IdType="pubmed">27185810</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnston CA, Stanton BR, Turner MR, et al Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London. J Neurol 2006; 253: 1642&#x2013;1643.</Citation><ArticleIdList><ArticleId IdType="pubmed">17219036</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan M, Heverin M, McLaughlin RL, Hardiman O. Lifetime risk and heritability of amyotrophic lateral sclerosis. JAMA Neurol 2019; 76: 1367.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6646974</ArticleId><ArticleId IdType="pubmed">31329211</ArticleId></ArticleIdList></Reference><Reference><Citation>Manjaly ZR, Scott KM, Abhinav K, et al The sex ratio in amyotrophic lateral sclerosis: a population based study. Amyotroph Lateral Scler 2010; 11: 439&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6485484</ArticleId><ArticleId IdType="pubmed">20225930</ArticleId></ArticleIdList></Reference><Reference><Citation>Al&#x2010;Chalabi A, Fang F, Hanby MF, et al An estimate of amyotrophic lateral sclerosis heritability using twin data. J Neurol Neurosurg Psychiatry 2010; 81: 1324&#x2013;1326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2988617</ArticleId><ArticleId IdType="pubmed">20861059</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, et al Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993; 362: 59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, Blair IP, Tripathi VB, et al TDP&#x2010;43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008; 319: 1668&#x2013;1672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, Valdmanis PN, Dion P, et al TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet 2008; 40: 572&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">18372902</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, et al Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009; 323: 1205&#x2013;1208.</Citation><ArticleIdList><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, Rogelj B, Hortobagyi T, et al Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009; 323: 1208&#x2013;1211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus&#x2010;Hernandez M, Mackenzie IR, Boeve BF, et al Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p&#x2010;linked FTD and ALS. Neuron 2011; 72: 245&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et al A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21&#x2010;linked ALS&#x2010;FTD. Neuron 2011; 72: 257&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli ET, Lasseigne BN, Petrovski S, et al Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science 2015; 347: 1436&#x2013;1441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4437632</ArticleId><ArticleId IdType="pubmed">25700176</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A, Wieland T, Richter B, et al Haploinsufficiency of TBK1 causes familial ALS and fronto&#x2010;temporal dementia. Nat Neurosci 2015; 18: 631&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">25803835</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Ber I, De Septenville A, Millecamps S, et al TBK1 mutation frequencies in French frontotemporal dementia and amyotrophic lateral sclerosis cohorts. Neurobiol Aging 2015; 36: 3116.e5&#x2013;3116.e8.</Citation><ArticleIdList><ArticleId IdType="pubmed">26476236</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, van Es MA, Hennekam EA, et al Evidence for an oligogenic basis of amyotrophic lateral sclerosis. Hum Mol Genet 2012; 21: 3776&#x2013;3784.</Citation><ArticleIdList><ArticleId IdType="pubmed">22645277</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Veldink JH, Saris CG, et al Genome&#x2010;wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet 2009; 41: 1083&#x2013;1087.</Citation><ArticleIdList><ArticleId IdType="pubmed">19734901</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden AC, Kim HJ, Hart MP, et al Ataxin&#x2010;2 intermediate&#x2010;length polyglutamine expansions are associated with increased risk for ALS. Nature 2010; 466: 1069&#x2013;1075.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, Veldink JH, van Blitterswijk M, et al Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2. Neurology 2011; 76: 2066&#x2013;2072.</Citation><ArticleIdList><ArticleId IdType="pubmed">21562247</ArticleId></ArticleIdList></Reference><Reference><Citation>Pupillo E, Poloni M, Bianchi E, et al Trauma and amyotrophic lateral sclerosis: a European population&#x2010;based case&#x2013;control study from the EURALS consortium. Amyotroph Lateral Scler Frontotemporal Degener 2018; 19: 118&#x2013;125.</Citation><ArticleIdList><ArticleId IdType="pubmed">29063790</ArticleId></ArticleIdList></Reference><Reference><Citation>Al&#x2010;Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 2013; 9: 617&#x2013;628.</Citation><ArticleIdList><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingre C, Roos PM, Piehl F, Kamel F, Fang F. Risk factors for amyotrophic lateral sclerosis. Clin Epidemiol 2015; 7: 181&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4334292</ArticleId><ArticleId IdType="pubmed">25709501</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Rademakers R, Neumann M. TDP&#x2010;43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol 2010; 9: 995&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pubmed">20864052</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature 2016; 539: 197&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585017</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng HX, Chen W, Hong ST, et al Mutations in UBQLN2 cause dominant X&#x2010;linked juvenile and adult&#x2010;onset ALS and ALS/dementia. Nature 2011; 477: 211&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3169705</ArticleId><ArticleId IdType="pubmed">21857683</ArticleId></ArticleIdList></Reference><Reference><Citation>Fecto F, Yan J, Vemula SP, et al SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol 2011; 68: 1440&#x2013;1446.</Citation><ArticleIdList><ArticleId IdType="pubmed">22084127</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruyama H, Morino H, Ito H, et al Mutations of optineurin in amyotrophic lateral sclerosis. Nature 2010; 465: 223&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pubmed">20428114</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JO, Mandrioli J, Benatar M, et al Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 2010; 68: 857&#x2013;864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3032425</ArticleId><ArticleId IdType="pubmed">21145000</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster CP, Smith EF, Bauer CS, et al The C9orf72 protein interacts with Rab1a and the ULK1 complex to regulate initiation of autophagy. EMBO J 2016; 35: 1656&#x2013;1676.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4969571</ArticleId><ArticleId IdType="pubmed">27334615</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, De Conti L, Stuani C, Romano M, Baralle M, Baralle F. Nuclear factor TDP&#x2010;43 can affect selected microRNA levels. FEBS J 2010; 277: 2268&#x2013;2281.</Citation><ArticleIdList><ArticleId IdType="pubmed">20423455</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems S, Bogaert E, Van Damme P, Van Den Bosch L. Inside out: the role of nucleocytoplasmic transport in ALS and FTLD. Acta Neuropathol 2016; 132: 159&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4947127</ArticleId><ArticleId IdType="pubmed">27271576</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vos KJ, Hafezparast M. Neurobiology of axonal transport defects in motor neuron diseases: opportunities for translational research? Neurobiol Dis 2017; 105: 283&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5536153</ArticleId><ArticleId IdType="pubmed">28235672</ArticleId></ArticleIdList></Reference><Reference><Citation>Bercier V, Hubbard JM, Fidelin K, et al Dynactin1 depletion leads to neuromuscular synapse instability and functional abnormalities. Mol Neurodegener 2019; 14: 27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6617949</ArticleId><ArticleId IdType="pubmed">31291987</ArticleId></ArticleIdList></Reference><Reference><Citation>Munch C, Sedlmeier R, Meyer T, et al Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS. Neurology 2004; 63: 724&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">15326253</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D, Yilmaz R, Muller K, et al Hot&#x2010;spot KIF5A mutations cause familial ALS. Brain 2018; 141: 688&#x2013;697.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837483</ArticleId><ArticleId IdType="pubmed">29342275</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas A, Kenna KP, Renton AE, et al Genome&#x2010;wide analyses identify KIF5A as a novel ALS gene. Neuron 2018; 97: 1268&#x2013;1283 e1266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5867896</ArticleId><ArticleId IdType="pubmed">29566793</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravits JM, La Spada AR. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology 2009; 73: 805&#x2013;811.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739608</ArticleId><ArticleId IdType="pubmed">19738176</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Wicks P, Brownstein CA, et al Concordance between site of onset and limb dominance in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2011; 82: 853&#x2013;854.</Citation><ArticleIdList><ArticleId IdType="pubmed">20562391</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon NG, Lomen&#x2010;Hoerth C, Kiernan MC. Patterns of clinical and electrodiagnostic abnormalities in early amyotrophic lateral sclerosis. Muscle Nerve 2014; 50: 894&#x2013;899.</Citation><ArticleIdList><ArticleId IdType="pubmed">24647900</ArticleId></ArticleIdList></Reference><Reference><Citation>
Motor Neurone Disease: Assessment and Management. London, UK: National Clinical Guideline Centre, 2016. 
https://www.ncbi.nlm.nih.gov/books/NBK349620/
</Citation></Reference><Reference><Citation>Jenkins TM, Alix JJP, Fingret J, et al Correction to: Longitudinal multi&#x2010;modal muscle&#x2010;based biomarker assessment in motor neuron disease. J Neurol 2020; 267: 257&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6954882</ArticleId><ArticleId IdType="pubmed">31781929</ArticleId></ArticleIdList></Reference><Reference><Citation>Parvizi J, Anderson SW, Martin CO, Damasio H, Damasio AR. Pathological laughter and crying: a link to the cerebellum. Brain 2001; 124: 1708&#x2013;1719.</Citation><ArticleIdList><ArticleId IdType="pubmed">11522574</ArticleId></ArticleIdList></Reference><Reference><Citation>Al&#x2010;Chalabi A, Hardiman O, Kiernan MC, Chio A, Rix&#x2010;Brooks B, van den Berg LH. Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurol 2016; 15: 1182&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pubmed">27647646</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Calvo A, Moglia C, Mazzini L, Mora G. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry 2011; 82: 740&#x2013;746.</Citation><ArticleIdList><ArticleId IdType="pubmed">21402743</ArticleId></ArticleIdList></Reference><Reference><Citation>Pringle CE, Hudson AJ, Munoz DG, Kiernan JA, Brown WF, Ebers GC. Primary lateral sclerosis. Clinical features, neuropathology and diagnostic criteria. Brain 1992; 115: 495&#x2013;520.</Citation><ArticleIdList><ArticleId IdType="pubmed">1606479</ArticleId></ArticleIdList></Reference><Reference><Citation>Finegan E, Chipika RH, Li Hi Shing S, Hardiman O, Bede P. Pathological crying and laughing in motor neuron disease: pathobiology, screening, intervention. Front Neurol 2019; 10: 260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6438102</ArticleId><ArticleId IdType="pubmed">30949121</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijesekera LC, Mathers S, Talman P, et al Natural history and clinical features of the flail arm and flail leg ALS variants. Neurology 2009; 72: 1087&#x2013;1094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2821838</ArticleId><ArticleId IdType="pubmed">19307543</ArticleId></ArticleIdList></Reference><Reference><Citation>Niven E, Newton J, Foley J, et al Validation of the Edinburgh cognitive and behavioural amyotrophic lateral sclerosis screen (ECAS): a cognitive tool for motor disorders. Amyotroph Lateral Scler Frontotemporal Degener 2015; 16: 172&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">25967542</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, et al Amyotrophic lateral sclerosis &#x2013; frontotemporal spectrum disorder (ALS&#x2010;FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener. 2017; 18: 153&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Diekstra FP, van Vught PW, van Rheenen W, et al UNC13A is a modifier of survival in amyotrophic lateral sclerosis. Neurobiol Aging 2012; 33: 630.e3&#x2013;630.e8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22118904</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng HJ, Debray TPA, Visser AE, et al Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol 2018; 17: 423&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Amyotrophic lateral sclerosis mimic syndromes: a population&#x2010;based study. Arch Neurol 2000; 57: 109&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">10634456</ArticleId></ArticleIdList></Reference><Reference><Citation>Huijbers MG, Niks EH, Klooster R, et al Myasthenia gravis with muscle specific kinase antibodies mimicking amyotrophic lateral sclerosis. Neuromuscul Disord 2016; 26: 350&#x2013;353.</Citation><ArticleIdList><ArticleId IdType="pubmed">27133662</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills KR. Detecting fasciculations in amyotrophic lateral sclerosis: duration of observation required. J Neurol Neurosurg Psychiatry 2011; 82: 549&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pubmed">20462913</ArticleId></ArticleIdList></Reference><Reference><Citation>De Schaepdryver M, Jeromin A, Gille B, et al Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2018; 89: 367&#x2013;373.</Citation><ArticleIdList><ArticleId IdType="pubmed">29054919</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Feneberg E, Weishaupt J, et al Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry 2016; 87: 12&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">26296871</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K, De Schaepdryver M, Stubendorff B, et al Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology 2017; 88: 2302&#x2013;2309.</Citation><ArticleIdList><ArticleId IdType="pubmed">28500227</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol 2011; 7: 639&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pubmed">21989247</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagani M, Chio A, Valentini MC, et al Functional pattern of brain FDG&#x2010;PET in amyotrophic lateral sclerosis. Neurology 2014; 83: 1067&#x2013;1074.</Citation><ArticleIdList><ArticleId IdType="pubmed">25122207</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Laere K, Vanhee A, Verschueren J, et al Value of 18fluorodeoxyglucose&#x2010;positron&#x2010;emission tomography in amyotrophic lateral sclerosis: a prospective study. JAMA Neurol 2014; 71: 553&#x2013;561.</Citation><ArticleIdList><ArticleId IdType="pubmed">24615479</ArticleId></ArticleIdList></Reference><Reference><Citation>Roggenbuck J, Quick A, Kolb SJ. Genetic testing and genetic counseling for amyotrophic lateral sclerosis: an update for clinicians. Genet Med 2017; 19: 267&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">27537704</ArticleId></ArticleIdList></Reference><Reference><Citation>Vajda A, McLaughlin RL, Heverin M, et al Genetic testing in ALS: a survey of current practices. Neurology 2017; 88: 991&#x2013;999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333513</ArticleId><ArticleId IdType="pubmed">28159885</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose&#x2010;ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996; 347: 1425&#x2013;1431.</Citation><ArticleIdList><ArticleId IdType="pubmed">8676624</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinchcliffe M, Smith A. Riluzole: real&#x2010;world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis. Degener Neurol Neuromuscul Dis 2017; 7: 61&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6053101</ArticleId><ArticleId IdType="pubmed">30050378</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing G, Edaravone ALSSG. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double&#x2010;blind, placebo&#x2010;controlled trial. Lancet Neurol 2017; 16: 505&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Al&#x2010;Chalabi A, Andersen PM, Chandran S, et al July 2017 ENCALS statement on edaravone. Amyotroph Lateral Scler Frontotemporal Degener 2017; 18: 471&#x2013;474.</Citation><ArticleIdList><ArticleId IdType="pubmed">28975816</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora JS, Genge A, Chio A, et al Masitinib as an add&#x2010;on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Frontotemporal Degener 2020; 21: 5&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">31280619</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM, Abrahams S, Borasio GD, et al EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS) &#x2013; revised report of an EFNS task force. Eur J Neurol 2012; 19: 360&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pubmed">21914052</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith RA, Miller TM, Yamanaka K, et al Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 2006; 116: 2290&#x2013;2296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1518790</ArticleId><ArticleId IdType="pubmed">16878173</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J, Zhu Q, Gendron TF, et al Gain of toxicity from ALS/FTD&#x2010;linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC&#x2010;containing RNAs. Neuron 2016; 90: 535&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860075</ArticleId><ArticleId IdType="pubmed">27112497</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzini L, Mareschi K, Ferrero I, et al Stem cell treatment in amyotrophic lateral sclerosis. J Neurol Sci 2008; 265: 78&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">17582439</ArticleId></ArticleIdList></Reference><Reference><Citation>Deda H, Inci MC, Kurekci AE, et al Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow&#x2010;derived hematopoietic stem cell transplantation: a 1&#x2010;year follow&#x2010;up. Cytotherapy 2009; 11: 18&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">19012065</ArticleId></ArticleIdList></Reference><Reference><Citation>Moviglia GA, Moviglia&#x2010;Brandolino MT, Varela GS, et al Feasibility, safety, and preliminary proof of principles of autologous neural stem cell treatment combined with T&#x2010;cell vaccination for ALS patients. Cell Transplant 2012; 21: S57&#x2013;S63.</Citation><ArticleIdList><ArticleId IdType="pubmed">22507681</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>